Role of FGF2 in promoting osteogenic differentiation for craniofacial bone regeneration

Area of Science:

• Regenerative Medicine
• Developmental Biology
• Cell Biology

Background:

• Fibroblast growth factor II (FGF2), also known as basic fibroblast growth factor (bFGF), is a key regulator in bone and craniofacial development.
• FGF2 influences critical cellular processes including survival, proliferation, migration, multilineage differentiation, and stemness in stromal cells.
• Existing research on FGF2 for craniofacial tissue repair presents inconsistencies due to its complex, multifunctional nature and dependency on various administration factors.

Purpose of the Study:

• To review the signaling pathways and mechanisms of FGF2 in osteogenic differentiation of human mesenchymal stromal cells (hMSCs).
• To discuss the application of FGF2 in craniofacial bone regeneration, considering in vitro, in vivo, and clinical contexts.
• To clarify the role of FGF2 in inducing osteogenic differentiation for improved craniofacial bone repair strategies.

Main Methods:

• Literature review of FGF2 signaling pathways and mechanisms.
• Analysis of in vitro studies on FGF2 effects on hMSCs.
• Examination of in vivo and clinical data regarding FGF2 in craniofacial bone regeneration.

Main Results:

• FGF2 signaling pathways are crucial for osteogenic differentiation of hMSCs.
• The efficacy of FGF2 in bone regeneration is highly dependent on dose, timing, duration, delivery pattern, and microenvironment.
• In vitro and in vivo studies demonstrate FGF2's potential, but clinical translation requires careful consideration of these variables.

Conclusions:

• FGF2 holds significant promise for enhancing craniofacial bone regeneration through osteogenic differentiation of hMSCs.
• Optimizing FGF2 delivery parameters is essential for consistent and effective therapeutic outcomes.
• Further research integrating in vitro, in vivo, and clinical findings is needed to fully harness FGF2's regenerative potential.